genitourinary tumours, prostate

Annals of Oncology 25 (Supplement 4): iv255–iv279, 2014
doi:10.1093/annonc/mdu336.38
790P
ACTIVITY OF SEQUENTIAL NEW DRUGS (NDS)
POST-DOCETAXEL (DOC) FAILURE, IN METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
PATIENTS (PTS). UPDATE FROM A MULTICENTER ITALIAN
EXPERIENCE
Aim: Abiraterone acetate (AA), cabazitaxel (CABA), and enzalutamide (ENZ) may
prolong survival in mCRPC pts progressing after DOC, although it is not clear how to use
NDs, to best exploit their efficacy and avoiding their possible cross resistances. We report
Table: 790P
3rd
line
eval
pts
4th
line
bRR
(%)
oRR
(%)
Sequence
eval
pts
bRR
(%)
oRR
(%)
median
PFS
(months)
median
PFS
(months)
AA post
CABA
AA post
ENZ
CABA
post
AA
CABA
post
ENZ
ENZ post
AA
ENZ post
CABA
68
28
18
4
4
25
25
1
12
8
0
3
6
0
0
2
88
28
16
4
2
50
0
NE
16
25
12
4
10
20
20
3
49
20
10
3
5
20
0
4
21
14
9
5
10
0
0
3
Conclusions: To our knowledge this retrospective study reports the highest number of
pts treated post-DOC with at least 2 NDs and it is the first to provide 4th-line data. It
appears from our findings that similar bRR and oRR are achieved by CABA and ENZ
while AA seems less active in 3rd line and responses in 4th line are rare.
Disclosure: O. Caffo: Honoraria from Sanofi-Aventis and Janssen-Cilag; U. De Giorgi,
R. Sabbatini and G. Procopio: Honoraria from Janssenn; P.A. Zucali: Honoraria from
Janssenn and Sanofi-Aventis. All other authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: [email protected].
Downloaded from http://annonc.oxfordjournals.org/ by guest on January 28, 2015
O. Caffo1, U. De Giorgi2, L. Fratino3, G. Facchini4, U. Basso5, D. Alesini6,
D. Gasparro7, C. Ortega8, M. Tucci9, F. Verderame10, E. Campadelli11, G. Lo Re12,
R. Sabbatini13, M. Donini14, G. Procopio15, D. Sartori16, P.A. Zucali17,
F. Carrozza18, A. D’Angelo19, F. Morelli20
1
Oncology, S. Chiara Hospital, Trento, ITALY
2
Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura
dei Tumori (I.R.S.T.), Meldola, Meldola (FC), ITALY
3
Medical Oncology, CRO Aviano, Aviano, ITALY
4
Medical Oncology, NCI Pascale, Naples, ITALY
5
Medical Oncology, IOV-IRCCS, Padua, ITALY
6
Department of Radiological, Oncological and Anatomopathological Sciences, La
Sapienza University of Rome, Rome, ITALY
7
Medical Oncology, Civil Hospital, Parma, ITALY
8
Medical Oncology, IRCC - Fondazione Piemontese per la Ricerca sul Cancro,
Candiolo, ITALY
9
Medical Oncology, University of Turin, Orbassano, ITALY
10
Medical Oncology, Villa Sofia Cervello Hospital, Palermo, ITALY
11
Medical Oncology, Civil Hospital, Lugo di Romagna, ITALY
12
Oncology, Medical Oncology, Pordenone, ITALY
13
Medical Oncology, Ospedale Policlinico-Modena, Modena, ITALY
14
Medical Oncology, Civil Hospital, Cremona, ITALY
15
Oncologia Medica, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan,
ITALY
16
Medical Oncology, Civil Hospital, Mirano, ITALY
17
Department of Oncology, Humanitas Cancer Center IRCCS, Rozzano, ITALY
18
Medical Oncology, Civil Hospital, Faenza, ITALY
19
Medical Oncology, Civil Hospital, Taormina, ITALY
20
Oncohematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni
Rotondo, ITALY
updated results (preliminary data reported at ASCO 2014) from a large series of pts,
receiving 2 NDs (or 3 in a limited series) after DOC progression in routine clinical practice.
Methods: All NDs were available in Italy through a compassionate use program
(CUP), or after the regulatory authorities approval (Only CABA in 2012 and AA in
2013). Based on a multi-institutional collaboration, we collected data of pts who
received at least 2 NDs after DOC.
Results: A consecutive series of 254 mCRPC pts, median age 71 yrs (46-91), with bone
(89%), nodal (56%) or visceral (20%) mets, was identified. All received NDs as 2nd and
3rd line after DOC, but 37 also as 4th line. The biochemical response rate (bRR)
(PSA ≥ 50%) was 37% in 2nd line, 24% in 3rd and 34% in 4th line, while the rate of
objective response (oRR) was 14%, 14% and 11%, respectively, and the median PFS was
6, 4 and 3 months, respectively. The table reports the outcomes of AA, CABA and ENZ
according to the sequence adopted.
abstracts
genitourinary tumours, prostate

Download Report